Nutraceuticals safety and efficacy in migraine without aura in a population of children affected by neurofibromatosis type I

Neurological Sciences

Volumn 34, Issue 11, 2013, Pages 1905-1909

  Carotenuto, Marco ^a   Esposito, Maria ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Children; Ginkolide B; Migraine without Aura; Neurofibromatosis type 1; Nutraceutical complex

Indexed keywords

GINKGOLIDE B COENZYME Q10 RIBOFLAVIN MAGNESIUM COMPLEX; NUTRACEUTICAL; UNCLASSIFIED DRUG;

ARTICLE; CHILD; CLINICAL EFFECTIVENESS; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE DURATION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; HUMAN; INFANT; MIGRAINE; NEUROFIBROMATOSIS; NEUROPROTECTION; OUTCOME ASSESSMENT; RATING SCALE; SCHOOL CHILD; SCORING SYSTEM;

CHILD; DIETARY SUPPLEMENTS; FEMALE; GINKGOLIDES; HUMANS; LACTONES; MAGNESIUM; MALE; MIGRAINE WITHOUT AURA; NEUROFIBROMATOSIS 1; RIBOFLAVIN; UBIQUINONE;

EID: 84888300380     PISSN: 15901874     EISSN: 15903478     Source Type: Journal    
DOI: 10.1007/s10072-013-1403-z     Document Type: Article

References (59)

1. OMIM™. Online Mendelian Inheritance in Men™ (2004) McKusick catalog of human genes. Johns Hopkins University Library, Johns Hopkins University Press, Baltimore, http://www.ncbi.nlm.nih.gov/omim
2. Huson SM, Hughes RAC (1994) The neurofibromatoses. A pathogenetic and clinical overview. Chapman & Hall, London
3. Friedman J, Gutman DH, McCollin M, Riccardi VM (1999) Neurofibromatosis Phenotype, Natural History and Pathogenesis. Johns Hopkins University Press, Baltimore
4. Cnossen MH, Moon KGM, Garssen MPJ et al (1998) Minor disease features in neurofibromatosis type 1 (NF1) and their possible value in diagnosis of NF1 children<6 years and clinically suspected of having NF1. J Med Genet 35:624-627
5. Ruggieri M (1999) The different forms of neurofibromatosis. Child's Nerv Syst 15:295-308
6. Upadhyaya M, Cooper DN (1998) Neurofibromatosis type 1. From genotype to phenotype, Bios Scientific, Oxford
7. Ashwal S, Rust R (2003) Child neurology in the 20th century. Pediatr Res 53:345-361
8. Hughes RAC (1994) Neurological complications of neurofibromatosis type 1. In: Huson SM, Hughes RAC (eds) The neurofibromatoses. A pathogenetic and clinical overview. Chapman & Hall, London, pp 204-232
9. Creange A, Zeller J, Roastaing-Rigattieri S et al (1999) Neurological complications of neurofibromatosis type 1 in adulthood. Brain 122:473-481
10. Riccardi VM (1986) Neurofibromatosis. Phenotype, Natural History and Pathogenesis, Johns Hopkins University Press, London
11. Dunn DW (1987) Neurofibromatosis in childhood. Curr Probl Pediatr 17(8):445-497
12. Schorry EK, Stowens DW, Crawford AH, Stowens PA, Schwartz WR, Dignan PS (1989) Summary of patient data from a multidisciplinary neurofibromatosis clinic. Neurofibromatosis 2:129-134
13. Clementi M, Battistella PA, Rizzi L, Boni S, Tenconi R (1996) Headache in patients with neurofibromatosis type 1. Headache 36(1):10
14. DiMario FJ Jr, Langshur S (2000) Headaches in patients with neurofibromatosis-1. J Child Neurol 15(4):235-238
15. Kernick D, Campbell J (2009) Measuring the impact of headache in children: a critical review of the literature. Cephalalgia 29:3-16
16. Heuschkel R, Kim S, Korf B, Schneider G, Bousvaros A (2001) Abdominal migraine in children with neurofibromatosis type 1: a case series and review of gastrointestinal involvement in NF1. J Pediatr Gastroenterol Nutr 33(2):149-154
17. Maizels M, Blumenfeld A, Burchette R (2004) A combination of riboflavin, magnesium, and fever few for migraine prophylaxis: a randomized trial. Headache 44:885-890
18. Condo M, Posar A, Arbizzani A, Parmeggiani A (2009) Riboflavin prophylaxis in pediatric and adolescent migraine. J Headache Pain 10:361-365. doi: 10.1007/s10194-009-0142-2
19. Castelli S, Meossi C, Domenici R, Fontana F, Stefani G (1993) Magnesium in the prophylaxis of primary headache and other periodic disorders in children. Pediatr Med Chir 15(5):481-488
20. ++concentration and electromyographical ischemic test in juvenile headache. Cephalalgia 19:802-809
21. Mauskop A, Altura BM (1998) Role of magnesium in the pathogenesis and treatment of migraines. Clin Neurosci 5:24-27
22. Wang F, Van Den Eeden SK, Ackerson LM et al (2003) Oral magnesium oxide prophylaxis of frequent migrainous headache in children: a randomized, double-blind, placebo-controlled trial. Headache 43:601-610
23. Sàndor S, Di Clemente L, Coppola G et al (2005) Efficacy of coenzyme Q10 in migraine prophylaxis: a randomized controlled trial. Neurology 64:713
24. Menke T (2008) Coenzyme Q10 in childhood: detection methods, reference values and disease-related changes in the coenzyme Q10 status. Georgian Med News 156:24-32
25. Peres MFP (2005) Melatonin, the pineal gland and their implications for headache disorders. Cephalalgia 25:403-411
26. Miano S, Parisi P, Pelliccia A, Luchetti A, Paolino MC, Villa MP (2008) Melatonin to prevent migraine or tension-type headache in children. Neurol Sci 29:285-287
27. Owen JM, Green BN (2004) Homeopathic treatment of headaches: a systematic review of the literature. J Chiropr Med 3(2):45-52
28. D'Andrea G, Bussone G, Allais G, Aguggia M, D'Onofrio F, Maggio M, Moschiano F, Saracco MG, Terzi MG, Petretta V, Benedetto C (2009) Efficacy of Ginkolide B in the prophylaxis of migraine with aura. Neurol Sci 30(Suppl 1):S121-S124
29. Esposito M, Carotenuto M (2011) Ginkgolide B complex efficacy for brief prophylaxis of migraine in school-aged children: an open-label study. Neurol Sci. 32(1):79-81. doi: 10.1007/s10072-010-0411-5
30. Esposito M, Ruberto M, Pascotto A, Carotenuto M (2012) Nutraceutical preparations in childhood migraine prophylaxis: effects on headache outcomes including disability and behaviour. Neurol Sci 33(6):1365-1368. doi: 10.1007/s10072-012-1019-8
31. van Beek TA (2005) Ginkgolides and bilobalide: their physical, chromatographic and spectroscopic properties. Bioorg Med Chem 13:5001-5012
32. Vogensen SB, Stromgaard K, Shindou H, Jaracz S, Suehiro M, Ishii S et al (2003) Preparation of 7-substituted ginkgolide derivatives: potent platelet activating factor (PAF) receptor antagonists. J Med Chem 46:601-608
33. Headache Classification Subcommittee of the International Headache Society (2004) The International Classification of Headache Disorders, edn 2. Cephalalgia 24(Suppl 1):1-15
34. Hershey AD, Powers SW, Vockell AL, LeCates S, Kabbouche MA, Maynard MK (2001) PedMIDAS: development of a questionnaire to assess disability of migraines in children. Neurology 57(11):2034-2039
35. Neurofibromatosis. Conference statement. (1988) National Institutes of Health Consensus Conference. Arch Neurol 45:575-578
36. Hachon C, Iannuzzi S, Chaix Y (2011) Behavioural and cognitive phenotypes in children with neurofibromatosis type 1 (NF1): the link with the neurobiological level. Brain Dev 33(1):52-61. doi: 10.1016/j.braindev.2009.12. 008
37. Gutmann DH, Aylsworth A, Carey JC et al (1997) The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. JAMA 278(1):51-57
38. Banerjee S, Crouse NR, Emnett RJ, Gianino SM, Gutmann DH (2011) Neurofibromatosis-1 regulates mTOR-mediated astrocyte growth and glioma formation in a TSC/Rheb-independent manner. Proc Natl Acad Sci USA 108(38):15996-16001. doi: 10.1073/pnas.1019012108
39. Tada K, Kochi M, Saya H, Kuratsu J, Shiraishi S, Kamiryo T, Shinojima N, Ushio Y (2003) Preliminary observations on genetic alterations in pilocytic astrocytomas associated with neurofibromatosis 1. Neuro Oncol 5(4):228-234
40. Elia M, Amato C, Bottitta M, Grillo L, Calabrese G, Esposito M, Carotenuto M (2012) An atypical patient with cowden syndrome and PTEN gene mutation presenting with cortical malformation and focal epilepsy. Brain Dev 34(10):873-876. doi: 10.1016/j.braindev.2012.03.005
41. Violante IR, Ribeiro MJ, Cunha G, Bernardino I, Duarte JV et al (2012) Abnormal brain activation in neurofibromatosis type 1: a link between visual processing and the default mode network. PLoS One 7(6):e38785. doi: 10.1371/journal.pone.0038785
42. Mautner VF, Kluwe L, Thakker SD, Leark RA (2002) Treatment of ADHD in neurofibromatosis type 1. Dev Med Child Neurol 44:164-170
43. Hyman SL, Arthur Shores E, North KN (2006) Learning disabilities in children with neurofibromatosis type 1: subtypes, cognitive profile, and attention-deficit-hyperactivity disorder. Dev Med Child Neurol 48:973-977
44. Friedman JM, Birch P, Greene C (1993) National neurofibromatosis foundation international database. Am J Med Genet 45:88-91
45. North K (2000) Neurofibromatosis type 1. Am J Med Genet 97:119-127
46. Levine TM, Materek A, Abel J, O'Donnell M, Cutting LE (2006) Cognitive profile of neurofibromatosis type 1. Semin Pediatr Neurol 13:8-20
47. Johnson H, Wiggs L, Stores G, Huson SM (2005) Psychological disturbance and sleep disorders in children with neurofibromatosis type 1. Dev Med Child Neurol 47(4):237-242
48. Reiter-Purtill J, Schorry EK, Lovell AM, Vannatta K, Gerhardt CA, Noll RB (2008) Parental distress, family functioning, and social support in families with and without a child with neurofibromatosis 1. J Pediatr Psychol 33(4):422-434
49. Noll RB, Reiter-Purtill J, Moore BD, Schorry EK, Lovell AM, Vannatta K, Gerhardt CA (2007) Social, emotional, and behavioral functioning of children with NF1. Am J Med Genet A 143A(19):2261-2273
50. Verrotti A, Agostinelli S, D'Egidio C et al (2012) Impact of a weight loss program on migraine in obese adolescents. Eur J Neurol doi: 10.1111/j.1468-1331201203771x
51. Bruni O, Galli F, Guidetti V (1999) Sleep hygiene and migraine in children and adolescents. Cephalalgia 19(Suppl 25):57-59
52. Carotenuto M, Gallai B, Parisi L, Roccella M, Esposito M (2013) Acupressure therapy for the insomnia in adolescents: a polysomnographic study. Neuropsychiatr Dis Treat 9:157-162. doi: 10.2147/NDT.S41892
53. Esposito M, Roccella M, Parisi L, Gallai B, Carotenuto M (2013) Hypersomnia in children affected by migraine without aura: a questionnaire-based case-control study. Neuropsychiatr Dis Treat 9:289-294. doi: 10.2147/NDT.S42182
54. Esposito M, Pascotto A, Gallai B et al (2012) Can headache impair intellectual abilities in children? An observational study. Neuropsychiatr Dis Treat 8:509-513. doi: 10.2147/NDT.S36863
55. Esposito M, Verrotti A, Gimigliano F et al (2012) Motor coordination impairment and migraine in children: a new comorbidity? Eur J Pediatr 171(11):1599-1604. doi: 10.1007/s00431-012-1759-8
56. Carotenuto M, Guidetti V, Ruju F, Galli F, Tagliente FR, Pascotto A (2005) Headache disorders as risk factors for sleep disturbances in school aged children. J Headache Pain 6(4):268-270
57. Vendrame M, Kaleyias J, Valencia I, Legido A, Kothare SV (2008) Polysomnographic findings in children with headaches. Pediatr Neurol 39(1):6-11
58. Carotenuto M, Esposito M, Precenzano F, Castaldo L, Roccella M (2011) Cosleeping in childhood migraine. Minerva Pediatr 63(2):105-109
59. Carotenuto M, Esposito M, Pascotto A (2010) Migraine and enuresis in children: an unusual correlation? Med Hypotheses 75(1):120-122. doi: 10.1016/j.mehy.2010.02.004